PMID- 23845726
OWN - NLM
STAT- MEDLINE
DCOM- 20131101
LR  - 20220309
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1830
IP  - 10
DP  - 2013 Oct
TI  - CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer 
      migration.
PG  - 4917-27
LID - S0304-4165(13)00293-6 [pii]
LID - 10.1016/j.bbagen.2013.06.033 [doi]
AB  - BACKGROUND: Chemokine ligand 2 (CCL2), also known as monocyte chemoattractant 
      protein-1 (MCP-1), belongs to the CC chemokine family which is associated with 
      the disease status and outcomes of cancers. Prostate cancer is the most commonly 
      diagnosed malignancy in men and shows a predilection for metastasis to the bone. 
      However, the effect of CCL2 on human prostate cancer cells is largely unknown. 
      The aim of this study was to examine the role of CCL2 in integrin expression and 
      migratory activity in prostate cancers. METHODS: Prostate cancer migration was 
      examined using Transwell, wound healing, and invasion assay. The PKCdelta and c-Src 
      phosphorylations were examined by using western blotting. The qPCR was used to 
      examine the mRNA expression of integrins. A transient transfection protocol was 
      used to examine AP-1 activity. RESULTS: Stimulation of prostate cancer cell lines 
      (PC3, DU145, and LNCaP) induced migration and expression of integrin alphavbeta3. 
      Treatment of cells with alphavbeta3 antibody or siRNA abolished CCL2-increased cell 
      migration. CCL2-increased migration and integrin expression were diminished by 
      CCR2 but not by CCR4 inhibitors, suggesting that the CCR2 receptor is involved in 
      CCL2-promoted prostate cancer migration. CCL2 activated a signal transduction 
      pathway that includes PKCdelta, c-Src, and AP-1. Reagents that inhibit specific 
      components of this pathway each diminished the ability of CCL2 to effect cell 
      migration and integrin expression. CONCLUSIONS: Interaction between CCL2 and CCR2 
      enhances migration of prostate cancer cells through an increase in alphavbeta3 integrin 
      production. GENERAL SIGNIFICANCE: CCL2 is a critical factor of prostate cancer 
      metastasis.
CI  - (c) 2013.
FAU - Lin, Tien-Huang
AU  - Lin TH
AD  - School of Chinese Medicine, China Medical University, Taichung, Taiwan.
FAU - Liu, Hsin-Ho
AU  - Liu HH
FAU - Tsai, Tsung-Hsun
AU  - Tsai TH
FAU - Chen, Chi-Cheng
AU  - Chen CC
FAU - Hsieh, Teng-Fu
AU  - Hsieh TF
FAU - Lee, Shang-Sen
AU  - Lee SS
FAU - Lee, Yuan-Ju
AU  - Lee YJ
FAU - Chen, Wen-Chi
AU  - Chen WC
FAU - Tang, Chih-Hsin
AU  - Tang CH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130709
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Integrin alphaVbeta3)
SB  - IM
MH  - Cell Line, Tumor
MH  - Chemokine CCL2/*metabolism
MH  - Humans
MH  - Integrin alphaVbeta3/*metabolism
MH  - Male
MH  - *Neoplasm Metastasis
MH  - Prostatic Neoplasms/*metabolism/pathology
OTO - NOTNLM
OT  - CCL2
OT  - CCR2
OT  - Integrin
OT  - Migration
OT  - Prostate cancer
EDAT- 2013/07/13 06:00
MHDA- 2013/11/02 06:00
CRDT- 2013/07/13 06:00
PHST- 2013/03/18 00:00 [received]
PHST- 2013/05/20 00:00 [revised]
PHST- 2013/06/28 00:00 [accepted]
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2013/11/02 06:00 [medline]
AID - S0304-4165(13)00293-6 [pii]
AID - 10.1016/j.bbagen.2013.06.033 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2013 Oct;1830(10):4917-27. doi: 
      10.1016/j.bbagen.2013.06.033. Epub 2013 Jul 9.